OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Focus
    • Neuropathic Corneal Pain
    • Rare Corneal Disease
  • Urcosimod
    • Mechanism of Action
    • Preclinical Data
  • NCP Expanded Access
  • Pipeline
    • Overview
    • Urcosimod Development Timeline
    • NEPTUNE Clinical trial
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • Analyst Coverage
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press releases
    • In The News
  • Contact
  • Linkedin
  • Twitter
Select Page
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit

by Paul | 19th May 2025 | News

London and New York, NY, May 19, 2025. OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, a severe ocular condition without an FDA approved therapy, and for...

Recent Posts

  • OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
  • OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences
  • OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
  • OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference
  • OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Urcosimod
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023